secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-071517
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026
--------------------------------------------------------------------------------

- Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.
- Cash $2.0B; 2026 GAAP op expenses guided $1.6-$1.7B with $180-$200M stock comp.
- Phase 3 RASolute 302 (daraxonrasib in 2L PDAC) readout expected H1 2026; enrollment complete.
- Initiated RASolute 305 (zoldonrasib in 1L PDAC); zoldonrasib FDA Breakthrough Therapy in NSCLC.
- New RAS(ON) inhibitor RMC-5127 entered clinic; new class RM-055 Phase 1 planned Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/0001193125-26-071517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/rvmd-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-071517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer